These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 12678836)
1. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Szewczyk JR; Laudeman C Curr Top Med Chem; 2003; 3(8):837-54. PubMed ID: 12678836 [TBL] [Abstract][Full Text] [Related]
2. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents. Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356 [TBL] [Abstract][Full Text] [Related]
3. Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol. Harikumar KG; Coudrat T; Desai AJ; Dong M; Dengler DG; Furness SGB; Christopoulos A; Wootten D; Sergienko EA; Sexton PM; Miller LJ Front Endocrinol (Lausanne); 2021; 12():789957. PubMed ID: 34950108 [TBL] [Abstract][Full Text] [Related]
4. Evidence for a functional role of cholecystokinin receptors in the rat thyroid gland. Ginda WJ Folia Histochem Cytobiol; 2001; 39(4):331-4. PubMed ID: 11766768 [TBL] [Abstract][Full Text] [Related]
5. The effect of centrally administered CCK-receptor antagonists on food intake in rats. Corp ES; Curcio M; Gibbs J; Smith GP Physiol Behav; 1997 Jun; 61(6):823-7. PubMed ID: 9177553 [TBL] [Abstract][Full Text] [Related]
6. Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats. Cohen H; Kaplan Z; Matar MA; Buriakovsky I; Bourin M; Kotler M Depress Anxiety; 2004; 20(3):139-52. PubMed ID: 15487014 [TBL] [Abstract][Full Text] [Related]
7. Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity. Dengler DG; Sun Q; Harikumar KG; Miller LJ; Sergienko EA SLAS Discov; 2022 Oct; 27(7):384-394. PubMed ID: 35850480 [TBL] [Abstract][Full Text] [Related]
8. Structural insights into human brain-gut peptide cholecystokinin receptors. Ding Y; Zhang H; Liao YY; Chen LN; Ji SY; Qin J; Mao C; Shen DD; Lin L; Wang H; Zhang Y; Li XM Cell Discov; 2022 Jun; 8(1):55. PubMed ID: 35672283 [TBL] [Abstract][Full Text] [Related]
10. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus. Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119 [TBL] [Abstract][Full Text] [Related]
11. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021 [TBL] [Abstract][Full Text] [Related]
12. Role of cholecystokinin and opioid peptides in control of food intake. Baile CA; McLaughlin CL; Della-Fera MA Physiol Rev; 1986 Jan; 66(1):172-234. PubMed ID: 2868468 [TBL] [Abstract][Full Text] [Related]
13. Role of cholecystokinin in the control of food intake. Peikin SR Gastroenterol Clin North Am; 1989 Dec; 18(4):757-75. PubMed ID: 2693351 [TBL] [Abstract][Full Text] [Related]
14. Major biological actions of CCK--a critical evaluation of research findings. Fink H; Rex A; Voits M; Voigt JP Exp Brain Res; 1998 Nov; 123(1-2):77-83. PubMed ID: 9835394 [TBL] [Abstract][Full Text] [Related]
15. Characteristics of the cholecystokinin-induced depolarization of pacemaking activity in cultured interstitial cells of Cajal from murine small intestine. Lee JH; Kim SY; Kwon YK; Kim BJ; So I Cell Physiol Biochem; 2013; 31(4-5):542-54. PubMed ID: 23571358 [TBL] [Abstract][Full Text] [Related]
16. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies. Galés C; Poirot M; Taillefer J; Maigret B; Martinez J; Moroder L; Escrieut C; Pradayrol L; Fourmy D; Silvente-Poirot S Mol Pharmacol; 2003 May; 63(5):973-82. PubMed ID: 12695525 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). de Tullio P; Delarge J; Pirotte B Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792 [TBL] [Abstract][Full Text] [Related]
19. Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target. Miller LJ; Desai AJ Trends Endocrinol Metab; 2016 Sep; 27(9):609-619. PubMed ID: 27156041 [TBL] [Abstract][Full Text] [Related]
20. CCK reduces the food intake mainly through CCK1R in Siberian sturgeon (Acipenser baerii Brandt). Zhang X; Tang N; Qi J; Wang S; Hao J; Wu Y; Chen H; Tian Z; Wang B; Chen D; Li Z Sci Rep; 2017 Sep; 7(1):12413. PubMed ID: 28963554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]